145 related articles for article (PubMed ID: 2567211)
1. Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies.
Hoskin DW; Stankova J; Anderson SK; Roder JC
Cancer Immunol Immunother; 1989; 29(3):226-30. PubMed ID: 2567211
[TBL] [Abstract][Full Text] [Related]
2. Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations.
Stanková J; Hoskin DW; Roder JC
Cell Immunol; 1989 Jun; 121(1):13-29. PubMed ID: 2470516
[TBL] [Abstract][Full Text] [Related]
3. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2-activated murine cell lines with macrophage- and B-lymphoblast-lytic activity.
Suzuki H; Ikemoto M; Yokoyama A; Kamitani T; Yamashita N; Maruyama M; Yano S
Cell Immunol; 1991 Jan; 132(1):127-39. PubMed ID: 1829651
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
6. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
7. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
Yang SC; Fry KD; Grimm EA; Roth JA
Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3-enhanced interleukin-2 immunotherapy of pulmonary metastases.
Kim B; Warnaka P; Konrad C
J Surg Res; 1991 May; 50(5):480-4. PubMed ID: 1828097
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
10. Sideways killing: the cytolysis of Fc receptor-bearing cells through bridging to cytolytic T lymphocytes by antibodies specific for the T-cell receptor-T3 complex.
Ito M; Usuba O; Unkeless JC; Schreiber R; Celada F; Bona CA; Moran TM
Scand J Immunol; 1989 Jun; 29(6):659-69. PubMed ID: 2525807
[TBL] [Abstract][Full Text] [Related]
11. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
Kikuchi T; Watanabe M; Ohno T
Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
13. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.
Moretta A; Poggi A; Pende D; Tripodi G; Orengo AM; Pella N; Augugliaro R; Bottino C; Ciccone E; Moretta L
J Exp Med; 1991 Dec; 174(6):1393-8. PubMed ID: 1720808
[TBL] [Abstract][Full Text] [Related]
14. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of non-MHC-restricted cytotoxicity by CD45 but not CD3 monoclonal antibodies in patients with large granular lymphoproliferative disease.
Starling GC; Davidson SE; Nimmo JC; Beard ME; Hart DN
Clin Exp Immunol; 1989 Dec; 78(3):396-401. PubMed ID: 2532991
[TBL] [Abstract][Full Text] [Related]
16. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
Azuma M; Cayabyab M; Buck D; Phillips JH; Lanier LL
J Exp Med; 1992 Feb; 175(2):353-60. PubMed ID: 1370679
[TBL] [Abstract][Full Text] [Related]
17. IL-4 regulation of a protein kinase C independent pathway for the generation of alpha CD3-induced activated killer cells.
Ting CC; Hargrove ME
Cell Immunol; 1992 Mar; 140(1):130-44. PubMed ID: 1531452
[TBL] [Abstract][Full Text] [Related]
18. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
19. A novel surface molecule expressed by long-term cultured T and natural killer cells is involved in cell activation.
Ferrini S; Cantoni C; Ciccone E; Biassoni R; Prigione I; Bottino C; Venzano P; Moretta L
Eur J Immunol; 1991 Sep; 21(9):1981-7. PubMed ID: 1832383
[TBL] [Abstract][Full Text] [Related]
20. Acute Trypanosoma cruzi infection differentially affects CD3 and Thy-1 mediated T cell activation.
de Oliveira GA; Gattass CR
Immunol Lett; 1991 Jun; 28(3):227-32. PubMed ID: 1679416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
